Rilzabrutinib ITP denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Rilzabrutinib for ITP as Not Medically Necessary

Cigna's medical-necessity denials for rilzabrutinib in immune thrombocytopenia (ITP) typically reflect a judgment that the submitted documentation does not clearly demonstrate that the patient's clinical situation requires this specific therapy at this time. Insurers apply internal coverage criteria — which may be more restrictive than the FDA-approved label — and will deny if those criteria appear unmet on paper, even when the prescriber believes the drug is clinically appropriate.

## Why This Denial Is Appealable

A medical-necessity denial is one of the most commonly overturned denial types on appeal. The insurer must show that a treatment is not medically necessary by the terms of your plan, not merely that it is expensive or that alternatives exist. If your chart supports the prescriber's clinical judgment, the denial record is often incomplete rather than correct.

Federal law gives you strong appeal rights: - ACA §2719 / ERISA §503 require a full-and-fair internal appeal with a written decision that specifically addresses the clinical rationale. - External review is available after an adverse internal decision. The federal window is generally up to approximately four months from the denial notice; confirm the exact deadline on your Explanation of Benefits. An independent review organization (IRO) — not the insurer — makes the final call. - Expedited review is available if a standard timeline would seriously jeopardize your health.

## Your Appeal Process and Timeline

1. Request the complete denial file (the Summary Plan Description, the clinical criteria applied, and the specific reason the criteria were not met) within days of receiving the denial. 2. File the internal appeal — typically due within 180 days of the denial notice, though your EOB controls. 3. If the internal appeal fails, request external review immediately.

## Documentation to Gather

• Diagnosis confirmation: pathology or laboratory results establishing ITP diagnosis, platelet trend records.
• Prior-treatment history: names of all prior ITP therapies tried, start/stop dates, and documented reasons for discontinuation (inadequate response, intolerance, or contraindication as noted in the chart).
• Clinical severity: chart notes documenting bleeding symptoms, platelet nadir values, and functional impact.
• Prescriber medical-necessity letter: a detailed letter from your hematologist explaining why rilzabrutinib is appropriate for your specific case, referencing the applicable ASH (American Society of Hematology) guideline recommendations and any relevant published clinical evidence.

## Criteria-Mapping Structure

Pull the two source documents: (1) the FDA-approved prescribing information for rilzabrutinib and (2) Cigna's current published medical coverage policy for this drug. List every requirement stated in those documents in a table, then provide the exact chart fact that satisfies each one. This side-by-side format forces the reviewer to engage with your evidence rather than issue a form denial.

Consult your prescriber and, if needed, a patient-advocacy organization before submitting — a well-organized appeal with complete documentation substantially improves outcomes.